[Effectiveness of pariet (rabeprazole) in the treatment of gastroesophageal reflux disease (at the reflux-esophagitis stage)].
The results on estimation of efficiency and safety of monotherapy by Rabeprasol in dose 20 mg per day in treatment of the gastroesophageal reflux disease in an open clinical investigation are presented. It was found 100% of Rabeprasol efficiency in healing of erosion and diffuse pathological changes of esophagus mucous at gastroesofageal reflux disease: in 18 from 20 patients--for 4 weeks (90%) and in one patient--for 8 weeks; ulcers of esophagus--for 8 weeks of treatment in one patient. This medicine showed safety use practically without any serious complications; the side effects were insignificant and did not require the cancellation or resort any other medications.
Vasil'ev
Iu V
IuV
Central Research Institute of Gastroenterology, Moscow.
Noskova
K K
KK
Zelenikin
S A
SA
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives; D064750:Rabeprazole
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D064750:Rabeprazole; D009853:Omeprazole